Enovis (NYSE:ENOV) Sees Unusually-High Trading Volume

Enovis Co. (NYSE:ENOVGet Rating) shares saw unusually-strong trading volume on Monday . Approximately 31,245 shares changed hands during mid-day trading, a decline of 93% from the previous session’s volume of 462,060 shares.The stock last traded at $51.55 and had previously closed at $50.54.

Analyst Ratings Changes

A number of equities analysts have recently commented on ENOV shares. Loop Capital reaffirmed a “buy” rating and issued a $68.00 target price on shares of Enovis in a report on Monday, June 27th. Argus began coverage on shares of Enovis in a research note on Tuesday, June 28th. They issued a “hold” rating on the stock. Canaccord Genuity Group began coverage on shares of Enovis in a research note on Monday. They issued a “buy” rating and a $67.00 price objective on the stock. Evercore ISI began coverage on shares of Enovis in a research note on Monday. They issued an “outperform” rating and a $68.00 price objective on the stock. Finally, Wells Fargo & Company dropped their price objective on shares of Enovis to $60.00 in a research note on Friday, July 22nd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $67.17.

Enovis Stock Down 4.9 %

The company has a market capitalization of $2.81 billion, a price-to-earnings ratio of 23.72, a price-to-earnings-growth ratio of 1.08 and a beta of 2.14. The company has a 50 day simple moving average of $55.28.

Enovis (NYSE:ENOVGet Rating) last posted its quarterly earnings results on Thursday, August 4th. The company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.10. Enovis had a net margin of 3.49% and a return on equity of 5.39%. The business had revenue of $395.12 million for the quarter, compared to analysts’ expectations of $400.23 million. During the same period in the prior year, the company posted $1.68 EPS. The business’s revenue for the quarter was up 11.0% on a year-over-year basis. Sell-side analysts predict that Enovis Co. will post 2.27 earnings per share for the current year.

Insider Transactions at Enovis

In other news, SVP Bradley J. Tandy sold 3,355 shares of the company’s stock in a transaction on Monday, August 8th. The shares were sold at an average price of $58.39, for a total transaction of $195,898.45. Following the transaction, the senior vice president now directly owns 13,845 shares of the company’s stock, valued at approximately $808,409.55. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 8.30% of the company’s stock.

Institutional Investors Weigh In On Enovis

Several institutional investors and hedge funds have recently made changes to their positions in the business. Paloma Partners Management Co purchased a new stake in shares of Enovis in the 2nd quarter worth about $209,000. Boenning & Scattergood Inc. purchased a new stake in shares of Enovis in the 2nd quarter worth about $210,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Enovis in the 2nd quarter valued at about $261,000. Victory Capital Management Inc. lifted its holdings in Enovis by 1.2% in the 2nd quarter. Victory Capital Management Inc. now owns 413,982 shares of the company’s stock valued at $22,769,000 after purchasing an additional 4,776 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Enovis in the 2nd quarter valued at about $285,000. 89.40% of the stock is currently owned by hedge funds and other institutional investors.

About Enovis

(Get Rating)

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.

See Also

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.